GPNMB and melanoma: Previous attempts to develop anti‐melanoma ADCs included DEDN6526A targeting endothelin B receptor (ETBR) [4] and glembatumumab vedotin targeting transmembrane glycoprotein NMB (GPNMB).[5] The two aforementioned ADCs, both carried antimitotic payload monomethyl auristatin E (MMAE), were not progressed beyond phase I and phase II trials, due to limited efficacy and dose‐limiting toxicity.